Patients With PIK3CA Mutations Less Likely to Benefit From Dual Anti-HER2 Inhibition
the Cancer Therapy Advisor take:
PIK3CA mutations were identified as possible predictive biomarkers of resistance to dual anti-human epidermal growth factor 2 (HER2) treatment for patients with breast cancer, according to an article published online in the journal The Oncologist.
Participants in this study included 121 patients with breast cancer who were positive for HER2. These patients were randomly assigned to neoadjuvant chemotherapy plus trastuzumab, lapatinib, or both trastuzumab and lapatinib.
The investigators collected pre- and post-treatment samples and evaluated them for HER2, p95-HER2, phosphorylated AKT (pAKT), phosphatase and tensin homolog, Ki67, apoptosis, and PIK3CA mutations.
Results showed 20% of the cases had a mutation in PIK3CA exon 20 or 9. Pathologic complete remission (pCR) rates were determined to be similar in PIK3CA wild-type (33.3%) and PIK3CA-mutated patients (22.7%; P=0.323).
Patients with PIK3CA wild-type tumors who were administered trastuzumab plus lapatinib experienced a higher probability of pCR (48.4% vs. 12.5%; P=0.06).
Furthermore, Ki67, pAKT, and apoptosis mutations were significantly decreased from baseline, as measured from the residual disease. Patients who received the dual anti-HER2 blockade demonstrated significantly greater degrees of Ki67 inhibition.
The gene expression and copy number data analysis revealed that a 50-gene signature specifically predicted pCR induced by lapatinib.
PIK3CA mutations possible predictive biomarkers of resistance to dual anti-human epidermal growth factor 2 treatment in breast cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Immunotherapy in Glioblastoma: Peaks and Pits
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed